nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SCN10A—melanoma	0.242	0.515	CbGaD
Lidocaine—EGFR—melanoma	0.175	0.372	CbGaD
Lidocaine—EGFR—Docetaxel—melanoma	0.117	0.327	CbGbCtD
Lidocaine—SLC22A5—Dactinomycin—melanoma	0.0532	0.149	CbGbCtD
Lidocaine—ABCB1—melanoma	0.0532	0.113	CbGaD
Lidocaine—CYP1A2—Carmustine—melanoma	0.0294	0.0821	CbGbCtD
Lidocaine—CYP1A2—Vemurafenib—melanoma	0.0232	0.0649	CbGbCtD
Lidocaine—CYP3A4—Temozolomide—melanoma	0.0222	0.062	CbGbCtD
Lidocaine—CYP2D6—Vemurafenib—melanoma	0.0191	0.0534	CbGbCtD
Lidocaine—CYP1A2—Dacarbazine—melanoma	0.0178	0.0497	CbGbCtD
Lidocaine—CYP3A7—Docetaxel—melanoma	0.0143	0.0399	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0143	0.0399	CbGbCtD
Lidocaine—ABCB1—Dactinomycin—melanoma	0.0135	0.0377	CbGbCtD
Lidocaine—CYP3A4—Vemurafenib—melanoma	0.0122	0.034	CbGbCtD
Lidocaine—CYP3A5—Docetaxel—melanoma	0.0107	0.0299	CbGbCtD
Lidocaine—ABCB1—Docetaxel—melanoma	0.00697	0.0195	CbGbCtD
Lidocaine—CYP3A4—Docetaxel—melanoma	0.00417	0.0117	CbGbCtD
Lidocaine—Teratogenicity—Carmustine—melanoma	0.00238	0.0433	CcSEcCtD
Lidocaine—Paralysis—Vemurafenib—melanoma	0.00136	0.0247	CcSEcCtD
Lidocaine—Hyperacusis—Temozolomide—melanoma	0.00129	0.0235	CcSEcCtD
Lidocaine—Meningitis—Carmustine—melanoma	0.00129	0.0234	CcSEcCtD
Lidocaine—Tocainide—SCN11A—melanoma	0.00108	0.208	CrCbGaD
Lidocaine—Local reaction—Bleomycin—melanoma	0.00103	0.0188	CcSEcCtD
Lidocaine—Neurotoxicity—Docetaxel—melanoma	0.000827	0.015	CcSEcCtD
Lidocaine—Hyperaesthesia—Bleomycin—melanoma	0.000728	0.0132	CcSEcCtD
Lidocaine—Burning sensation—Carmustine—melanoma	0.000718	0.0131	CcSEcCtD
Lidocaine—Levobupivacaine—SCN10A—melanoma	0.000672	0.129	CrCbGaD
Lidocaine—Procainamide—SCN11A—melanoma	0.000668	0.128	CrCbGaD
Lidocaine—Tenderness—Bleomycin—melanoma	0.000655	0.0119	CcSEcCtD
Lidocaine—Hyperaesthesia—Temozolomide—melanoma	0.000615	0.0112	CcSEcCtD
Lidocaine—Petechiae—Temozolomide—melanoma	0.000586	0.0107	CcSEcCtD
Lidocaine—Mepivacaine—SCN10A—melanoma	0.000548	0.105	CrCbGaD
Lidocaine—Skin exfoliation—Bleomycin—melanoma	0.000546	0.00992	CcSEcCtD
Lidocaine—Bupivacaine—SCN10A—melanoma	0.000537	0.103	CrCbGaD
Lidocaine—Neuropathy peripheral—Vemurafenib—melanoma	0.000517	0.0094	CcSEcCtD
Lidocaine—Chloroprocaine—SCN10A—melanoma	0.000509	0.0979	CrCbGaD
Lidocaine—Depressed level of consciousness—Carmustine—melanoma	0.000482	0.00876	CcSEcCtD
Lidocaine—Urinary incontinence—Carmustine—melanoma	0.000482	0.00876	CcSEcCtD
Lidocaine—Skin exfoliation—Carmustine—melanoma	0.000477	0.00866	CcSEcCtD
Lidocaine—Redness—Docetaxel—melanoma	0.000475	0.00863	CcSEcCtD
Lidocaine—Neuropathy—Carmustine—melanoma	0.000469	0.00851	CcSEcCtD
Lidocaine—Urinary incontinence—Temozolomide—melanoma	0.000466	0.00846	CcSEcCtD
Lidocaine—Depressed level of consciousness—Temozolomide—melanoma	0.000466	0.00846	CcSEcCtD
Lidocaine—Disorientation—Bleomycin—melanoma	0.000464	0.00843	CcSEcCtD
Lidocaine—Burning sensation—Docetaxel—melanoma	0.000462	0.00839	CcSEcCtD
Lidocaine—Skin exfoliation—Temozolomide—melanoma	0.00046	0.00837	CcSEcCtD
Lidocaine—Coma—Carmustine—melanoma	0.000456	0.00829	CcSEcCtD
Lidocaine—Neuropathy—Temozolomide—melanoma	0.000453	0.00823	CcSEcCtD
Lidocaine—Throat sore—Docetaxel—melanoma	0.000445	0.00809	CcSEcCtD
Lidocaine—Eye disorder—Vemurafenib—melanoma	0.000443	0.00805	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Docetaxel—melanoma	0.000441	0.00801	CcSEcCtD
Lidocaine—Cardiac disorder—Vemurafenib—melanoma	0.00044	0.00799	CcSEcCtD
Lidocaine—Ropivacaine—SCN10A—melanoma	0.000433	0.0832	CrCbGaD
Lidocaine—Angiopathy—Vemurafenib—melanoma	0.00043	0.00781	CcSEcCtD
Lidocaine—Chills—Vemurafenib—melanoma	0.000425	0.00773	CcSEcCtD
Lidocaine—Erythema—Vemurafenib—melanoma	0.000413	0.0075	CcSEcCtD
Lidocaine—Tocainide—SCN10A—melanoma	0.000407	0.0783	CrCbGaD
Lidocaine—Dysgeusia—Vemurafenib—melanoma	0.000404	0.00734	CcSEcCtD
Lidocaine—Back pain—Vemurafenib—melanoma	0.000399	0.00725	CcSEcCtD
Lidocaine—Diplopia—Carmustine—melanoma	0.000362	0.00658	CcSEcCtD
Lidocaine—Bronchospasm—Bleomycin—melanoma	0.000353	0.00641	CcSEcCtD
Lidocaine—Oropharyngeal pain—Docetaxel—melanoma	0.000353	0.00641	CcSEcCtD
Lidocaine—Diplopia—Temozolomide—melanoma	0.00035	0.00636	CcSEcCtD
Lidocaine—Anaphylactic shock—Vemurafenib—melanoma	0.000337	0.00612	CcSEcCtD
Lidocaine—Dysphagia—Dactinomycin—melanoma	0.000335	0.00608	CcSEcCtD
Lidocaine—Nervous system disorder—Vemurafenib—melanoma	0.00033	0.006	CcSEcCtD
Lidocaine—Hypotension—Vemurafenib—melanoma	0.000315	0.00572	CcSEcCtD
Lidocaine—Dysphagia—Carmustine—melanoma	0.000313	0.00569	CcSEcCtD
Lidocaine—Stomatitis—Bleomycin—melanoma	0.000312	0.00566	CcSEcCtD
Lidocaine—Skin exfoliation—Docetaxel—melanoma	0.000306	0.00556	CcSEcCtD
Lidocaine—Dysphagia—Temozolomide—melanoma	0.000303	0.0055	CcSEcCtD
Lidocaine—Neuropathy—Docetaxel—melanoma	0.000301	0.00547	CcSEcCtD
Lidocaine—Sweating increased—Temozolomide—melanoma	0.000295	0.00536	CcSEcCtD
Lidocaine—Stomatitis—Dactinomycin—melanoma	0.000291	0.00528	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Vemurafenib—melanoma	0.000291	0.00528	CcSEcCtD
Lidocaine—Haemoglobin—Bleomycin—melanoma	0.000289	0.00524	CcSEcCtD
Lidocaine—Haemorrhage—Bleomycin—melanoma	0.000287	0.00522	CcSEcCtD
Lidocaine—Lightheadedness—Docetaxel—melanoma	0.000287	0.00521	CcSEcCtD
Lidocaine—Hypoaesthesia—Bleomycin—melanoma	0.000286	0.00519	CcSEcCtD
Lidocaine—Neuropathy peripheral—Carmustine—melanoma	0.000274	0.00497	CcSEcCtD
Lidocaine—Stomatitis—Carmustine—melanoma	0.000272	0.00494	CcSEcCtD
Lidocaine—Flushing—Bleomycin—melanoma	0.000266	0.00484	CcSEcCtD
Lidocaine—Neuropathy peripheral—Temozolomide—melanoma	0.000264	0.00481	CcSEcCtD
Lidocaine—Stomatitis—Temozolomide—melanoma	0.000263	0.00478	CcSEcCtD
Lidocaine—Chills—Bleomycin—melanoma	0.000258	0.00468	CcSEcCtD
Lidocaine—Haemoglobin—Carmustine—melanoma	0.000252	0.00458	CcSEcCtD
Lidocaine—Procainamide—SCN10A—melanoma	0.000251	0.0483	CrCbGaD
Lidocaine—Haemorrhage—Carmustine—melanoma	0.000251	0.00455	CcSEcCtD
Lidocaine—Erythema—Bleomycin—melanoma	0.00025	0.00454	CcSEcCtD
Lidocaine—Hypoaesthesia—Carmustine—melanoma	0.000249	0.00453	CcSEcCtD
Lidocaine—Flushing—Dactinomycin—melanoma	0.000249	0.00452	CcSEcCtD
Lidocaine—Hypersensitivity—Vemurafenib—melanoma	0.000248	0.00451	CcSEcCtD
Lidocaine—Visual disturbance—Docetaxel—melanoma	0.000246	0.00446	CcSEcCtD
Lidocaine—Dermatitis bullous—Docetaxel—melanoma	0.000244	0.00443	CcSEcCtD
Lidocaine—Haemoglobin—Temozolomide—melanoma	0.000243	0.00442	CcSEcCtD
Lidocaine—Haemorrhage—Temozolomide—melanoma	0.000242	0.0044	CcSEcCtD
Lidocaine—Asthenia—Vemurafenib—melanoma	0.000242	0.00439	CcSEcCtD
Lidocaine—Visual impairment—Carmustine—melanoma	0.000242	0.00439	CcSEcCtD
Lidocaine—Hypoaesthesia—Temozolomide—melanoma	0.000241	0.00438	CcSEcCtD
Lidocaine—Chills—Dactinomycin—melanoma	0.00024	0.00437	CcSEcCtD
Lidocaine—Eye disorder—Carmustine—melanoma	0.000234	0.00426	CcSEcCtD
Lidocaine—Visual impairment—Temozolomide—melanoma	0.000233	0.00424	CcSEcCtD
Lidocaine—Erythema—Dactinomycin—melanoma	0.000233	0.00424	CcSEcCtD
Lidocaine—Flushing—Carmustine—melanoma	0.000233	0.00423	CcSEcCtD
Lidocaine—Eye disorder—Temozolomide—melanoma	0.000226	0.00411	CcSEcCtD
Lidocaine—Tinnitus—Temozolomide—melanoma	0.000226	0.0041	CcSEcCtD
Lidocaine—Flushing—Temozolomide—melanoma	0.000225	0.00408	CcSEcCtD
Lidocaine—Cardiac disorder—Temozolomide—melanoma	0.000225	0.00408	CcSEcCtD
Lidocaine—Dizziness—Vemurafenib—melanoma	0.000223	0.00405	CcSEcCtD
Lidocaine—Angiopathy—Temozolomide—melanoma	0.00022	0.00399	CcSEcCtD
Lidocaine—Immune system disorder—Temozolomide—melanoma	0.000219	0.00397	CcSEcCtD
Lidocaine—Erythema—Carmustine—melanoma	0.000218	0.00396	CcSEcCtD
Lidocaine—Chills—Temozolomide—melanoma	0.000217	0.00395	CcSEcCtD
Lidocaine—Vomiting—Vemurafenib—melanoma	0.000214	0.00389	CcSEcCtD
Lidocaine—Chest pain—Bleomycin—melanoma	0.000213	0.00387	CcSEcCtD
Lidocaine—Rash—Vemurafenib—melanoma	0.000212	0.00386	CcSEcCtD
Lidocaine—Dermatitis—Vemurafenib—melanoma	0.000212	0.00385	CcSEcCtD
Lidocaine—Back pain—Carmustine—melanoma	0.000211	0.00383	CcSEcCtD
Lidocaine—Headache—Vemurafenib—melanoma	0.000211	0.00383	CcSEcCtD
Lidocaine—Erythema—Temozolomide—melanoma	0.000211	0.00383	CcSEcCtD
Lidocaine—Dysgeusia—Temozolomide—melanoma	0.000206	0.00375	CcSEcCtD
Lidocaine—Confusional state—Bleomycin—melanoma	0.000206	0.00374	CcSEcCtD
Lidocaine—Vision blurred—Carmustine—melanoma	0.000206	0.00374	CcSEcCtD
Lidocaine—Tremor—Carmustine—melanoma	0.000204	0.00371	CcSEcCtD
Lidocaine—Anaphylactic shock—Bleomycin—melanoma	0.000204	0.00371	CcSEcCtD
Lidocaine—Oedema—Bleomycin—melanoma	0.000204	0.00371	CcSEcCtD
Lidocaine—Back pain—Temozolomide—melanoma	0.000204	0.00371	CcSEcCtD
Lidocaine—Dysphagia—Docetaxel—melanoma	0.000201	0.00366	CcSEcCtD
Lidocaine—Agitation—Carmustine—melanoma	0.000201	0.00364	CcSEcCtD
Lidocaine—Nausea—Vemurafenib—melanoma	0.0002	0.00363	CcSEcCtD
Lidocaine—Vision blurred—Temozolomide—melanoma	0.000199	0.00361	CcSEcCtD
Lidocaine—Bronchospasm—Docetaxel—melanoma	0.000198	0.0036	CcSEcCtD
Lidocaine—Tremor—Temozolomide—melanoma	0.000198	0.00359	CcSEcCtD
Lidocaine—Agitation—Temozolomide—melanoma	0.000194	0.00352	CcSEcCtD
Lidocaine—Angioedema—Temozolomide—melanoma	0.000193	0.0035	CcSEcCtD
Lidocaine—Hypotension—Bleomycin—melanoma	0.000191	0.00346	CcSEcCtD
Lidocaine—Oedema—Dactinomycin—melanoma	0.00019	0.00346	CcSEcCtD
Lidocaine—Convulsion—Carmustine—melanoma	0.000189	0.00343	CcSEcCtD
Lidocaine—Hypertension—Carmustine—melanoma	0.000188	0.00342	CcSEcCtD
Lidocaine—Chest pain—Carmustine—melanoma	0.000186	0.00337	CcSEcCtD
Lidocaine—Anxiety—Carmustine—melanoma	0.000185	0.00336	CcSEcCtD
Lidocaine—Paraesthesia—Bleomycin—melanoma	0.000183	0.00333	CcSEcCtD
Lidocaine—Convulsion—Temozolomide—melanoma	0.000183	0.00332	CcSEcCtD
Lidocaine—Hypertension—Temozolomide—melanoma	0.000182	0.00331	CcSEcCtD
Lidocaine—Dyspnoea—Bleomycin—melanoma	0.000182	0.0033	CcSEcCtD
Lidocaine—Confusional state—Carmustine—melanoma	0.00018	0.00326	CcSEcCtD
Lidocaine—Anxiety—Temozolomide—melanoma	0.000179	0.00325	CcSEcCtD
Lidocaine—Oedema—Carmustine—melanoma	0.000178	0.00324	CcSEcCtD
Lidocaine—Neuropathy peripheral—Docetaxel—melanoma	0.000176	0.0032	CcSEcCtD
Lidocaine—Stomatitis—Docetaxel—melanoma	0.000175	0.00318	CcSEcCtD
Lidocaine—Pain—Bleomycin—melanoma	0.000174	0.00317	CcSEcCtD
Lidocaine—Confusional state—Temozolomide—melanoma	0.000174	0.00315	CcSEcCtD
Lidocaine—Anaphylactic shock—Temozolomide—melanoma	0.000172	0.00313	CcSEcCtD
Lidocaine—Oedema—Temozolomide—melanoma	0.000172	0.00313	CcSEcCtD
Lidocaine—Nervous system disorder—Temozolomide—melanoma	0.000169	0.00307	CcSEcCtD
Lidocaine—Feeling abnormal—Bleomycin—melanoma	0.000168	0.00305	CcSEcCtD
Lidocaine—Hypotension—Carmustine—melanoma	0.000166	0.00302	CcSEcCtD
Lidocaine—Hyperhidrosis—Temozolomide—melanoma	0.000166	0.00302	CcSEcCtD
Lidocaine—Pain—Dactinomycin—melanoma	0.000163	0.00296	CcSEcCtD
Lidocaine—Urticaria—Bleomycin—melanoma	0.000162	0.00294	CcSEcCtD
Lidocaine—Haemoglobin—Docetaxel—melanoma	0.000162	0.00294	CcSEcCtD
Lidocaine—Rhinitis—Docetaxel—melanoma	0.000161	0.00293	CcSEcCtD
Lidocaine—Haemorrhage—Docetaxel—melanoma	0.000161	0.00293	CcSEcCtD
Lidocaine—Hypoaesthesia—Docetaxel—melanoma	0.00016	0.00291	CcSEcCtD
Lidocaine—Paraesthesia—Carmustine—melanoma	0.00016	0.00291	CcSEcCtD
Lidocaine—Dyspnoea—Carmustine—melanoma	0.000159	0.00288	CcSEcCtD
Lidocaine—Somnolence—Carmustine—melanoma	0.000158	0.00288	CcSEcCtD
Lidocaine—Feeling abnormal—Dactinomycin—melanoma	0.000157	0.00285	CcSEcCtD
Lidocaine—Visual impairment—Docetaxel—melanoma	0.000155	0.00282	CcSEcCtD
Lidocaine—Paraesthesia—Temozolomide—melanoma	0.000155	0.00281	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Carmustine—melanoma	0.000154	0.00279	CcSEcCtD
Lidocaine—Dyspnoea—Temozolomide—melanoma	0.000153	0.00279	CcSEcCtD
Lidocaine—Somnolence—Temozolomide—melanoma	0.000153	0.00278	CcSEcCtD
Lidocaine—Pain—Carmustine—melanoma	0.000152	0.00277	CcSEcCtD
Lidocaine—Eye disorder—Docetaxel—melanoma	0.000151	0.00273	CcSEcCtD
Lidocaine—Hypersensitivity—Bleomycin—melanoma	0.00015	0.00273	CcSEcCtD
Lidocaine—Flushing—Docetaxel—melanoma	0.000149	0.00272	CcSEcCtD
Lidocaine—Cardiac disorder—Docetaxel—melanoma	0.000149	0.00272	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Temozolomide—melanoma	0.000149	0.0027	CcSEcCtD
Lidocaine—Pain—Temozolomide—melanoma	0.000147	0.00267	CcSEcCtD
Lidocaine—Feeling abnormal—Carmustine—melanoma	0.000147	0.00267	CcSEcCtD
Lidocaine—Asthenia—Bleomycin—melanoma	0.000146	0.00266	CcSEcCtD
Lidocaine—Angiopathy—Docetaxel—melanoma	0.000146	0.00266	CcSEcCtD
Lidocaine—Immune system disorder—Docetaxel—melanoma	0.000145	0.00264	CcSEcCtD
Lidocaine—Chills—Docetaxel—melanoma	0.000145	0.00263	CcSEcCtD
Lidocaine—Feeling abnormal—Temozolomide—melanoma	0.000142	0.00258	CcSEcCtD
Lidocaine—Erythema—Docetaxel—melanoma	0.00014	0.00255	CcSEcCtD
Lidocaine—Hypersensitivity—Dactinomycin—melanoma	0.00014	0.00255	CcSEcCtD
Lidocaine—Dysgeusia—Docetaxel—melanoma	0.000137	0.00249	CcSEcCtD
Lidocaine—Urticaria—Temozolomide—melanoma	0.000137	0.00248	CcSEcCtD
Lidocaine—Asthenia—Dactinomycin—melanoma	0.000137	0.00248	CcSEcCtD
Lidocaine—Back pain—Docetaxel—melanoma	0.000136	0.00246	CcSEcCtD
Lidocaine—Hypersensitivity—Carmustine—melanoma	0.000131	0.00238	CcSEcCtD
Lidocaine—Vomiting—Bleomycin—melanoma	0.00013	0.00236	CcSEcCtD
Lidocaine—Rash—Bleomycin—melanoma	0.000129	0.00234	CcSEcCtD
Lidocaine—Dermatitis—Bleomycin—melanoma	0.000129	0.00233	CcSEcCtD
Lidocaine—Asthenia—Carmustine—melanoma	0.000128	0.00232	CcSEcCtD
Lidocaine—Hypersensitivity—Temozolomide—melanoma	0.000127	0.0023	CcSEcCtD
Lidocaine—Asthenia—Temozolomide—melanoma	0.000123	0.00224	CcSEcCtD
Lidocaine—Loss of consciousness—Docetaxel—melanoma	0.000123	0.00224	CcSEcCtD
Lidocaine—Convulsion—Docetaxel—melanoma	0.000121	0.00221	CcSEcCtD
Lidocaine—Nausea—Bleomycin—melanoma	0.000121	0.0022	CcSEcCtD
Lidocaine—Hypertension—Docetaxel—melanoma	0.000121	0.0022	CcSEcCtD
Lidocaine—Vomiting—Dactinomycin—melanoma	0.000121	0.0022	CcSEcCtD
Lidocaine—Rash—Dactinomycin—melanoma	0.00012	0.00218	CcSEcCtD
Lidocaine—Chest pain—Docetaxel—melanoma	0.000119	0.00217	CcSEcCtD
Lidocaine—Dizziness—Carmustine—melanoma	0.000118	0.00214	CcSEcCtD
Lidocaine—Confusional state—Docetaxel—melanoma	0.000115	0.0021	CcSEcCtD
Lidocaine—Oedema—Docetaxel—melanoma	0.000114	0.00208	CcSEcCtD
Lidocaine—Anaphylactic shock—Docetaxel—melanoma	0.000114	0.00208	CcSEcCtD
Lidocaine—Dizziness—Temozolomide—melanoma	0.000114	0.00207	CcSEcCtD
Lidocaine—Vomiting—Carmustine—melanoma	0.000113	0.00206	CcSEcCtD
Lidocaine—Nausea—Dactinomycin—melanoma	0.000113	0.00205	CcSEcCtD
Lidocaine—Shock—Docetaxel—melanoma	0.000113	0.00205	CcSEcCtD
Lidocaine—Rash—Carmustine—melanoma	0.000112	0.00204	CcSEcCtD
Lidocaine—Nervous system disorder—Docetaxel—melanoma	0.000112	0.00204	CcSEcCtD
Lidocaine—Dermatitis—Carmustine—melanoma	0.000112	0.00204	CcSEcCtD
Lidocaine—Headache—Carmustine—melanoma	0.000112	0.00203	CcSEcCtD
Lidocaine—Vomiting—Temozolomide—melanoma	0.000109	0.00199	CcSEcCtD
Lidocaine—Rash—Temozolomide—melanoma	0.000108	0.00197	CcSEcCtD
Lidocaine—Dermatitis—Temozolomide—melanoma	0.000108	0.00197	CcSEcCtD
Lidocaine—Headache—Temozolomide—melanoma	0.000108	0.00196	CcSEcCtD
Lidocaine—Hypotension—Docetaxel—melanoma	0.000107	0.00194	CcSEcCtD
Lidocaine—Nausea—Carmustine—melanoma	0.000106	0.00192	CcSEcCtD
Lidocaine—Paraesthesia—Docetaxel—melanoma	0.000103	0.00187	CcSEcCtD
Lidocaine—Nausea—Temozolomide—melanoma	0.000102	0.00186	CcSEcCtD
Lidocaine—Dyspnoea—Docetaxel—melanoma	0.000102	0.00185	CcSEcCtD
Lidocaine—Somnolence—Docetaxel—melanoma	0.000102	0.00185	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Docetaxel—melanoma	9.88e-05	0.0018	CcSEcCtD
Lidocaine—Pain—Docetaxel—melanoma	9.79e-05	0.00178	CcSEcCtD
Lidocaine—Feeling abnormal—Docetaxel—melanoma	9.43e-05	0.00171	CcSEcCtD
Lidocaine—Tocainide—ALB—melanoma	9.36e-05	0.018	CrCbGaD
Lidocaine—Hypersensitivity—Docetaxel—melanoma	8.43e-05	0.00153	CcSEcCtD
Lidocaine—Asthenia—Docetaxel—melanoma	8.21e-05	0.00149	CcSEcCtD
Lidocaine—Dizziness—Docetaxel—melanoma	7.57e-05	0.00137	CcSEcCtD
Lidocaine—Vomiting—Docetaxel—melanoma	7.28e-05	0.00132	CcSEcCtD
Lidocaine—Rash—Docetaxel—melanoma	7.22e-05	0.00131	CcSEcCtD
Lidocaine—Dermatitis—Docetaxel—melanoma	7.21e-05	0.00131	CcSEcCtD
Lidocaine—Headache—Docetaxel—melanoma	7.17e-05	0.0013	CcSEcCtD
Lidocaine—Nausea—Docetaxel—melanoma	6.8e-05	0.00124	CcSEcCtD
Lidocaine—CYP2C9—Metabolism—CYP17A1—melanoma	3.41e-06	3.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MDM2—melanoma	3.4e-06	3.05e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	3.38e-06	3.03e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—FASN—melanoma	3.38e-06	3.03e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.37e-06	3.02e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1B—melanoma	3.36e-06	3.02e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ABCB1—melanoma	3.36e-06	3.01e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB2—melanoma	3.35e-06	3.01e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—melanoma	3.35e-06	3e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—melanoma	3.33e-06	2.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—melanoma	3.33e-06	2.99e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	3.32e-06	2.98e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—melanoma	3.32e-06	2.98e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC5A5—melanoma	3.32e-06	2.98e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CB—melanoma	3.31e-06	2.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD4—melanoma	3.3e-06	2.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—melanoma	3.29e-06	2.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KDR—melanoma	3.28e-06	2.94e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—melanoma	3.28e-06	2.94e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	3.27e-06	2.93e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GNA11—melanoma	3.25e-06	2.91e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—melanoma	3.23e-06	2.9e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GNA11—melanoma	3.22e-06	2.89e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GNAQ—melanoma	3.21e-06	2.88e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CD44—melanoma	3.21e-06	2.88e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—FASN—melanoma	3.18e-06	2.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CTNNB1—melanoma	3.18e-06	2.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FN1—melanoma	3.16e-06	2.83e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PRKCA—melanoma	3.16e-06	2.83e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.16e-06	2.83e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—FASN—melanoma	3.15e-06	2.83e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ERCC2—melanoma	3.13e-06	2.81e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC5A5—melanoma	3.13e-06	2.81e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.12e-06	2.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1B—melanoma	3.11e-06	2.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1A—melanoma	3.1e-06	2.78e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC5A5—melanoma	3.1e-06	2.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—melanoma	3.1e-06	2.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOTCH1—melanoma	3.09e-06	2.77e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PRKCA—melanoma	3.09e-06	2.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NFKB1—melanoma	3.08e-06	2.76e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP1B1—melanoma	3.08e-06	2.76e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—melanoma	3.07e-06	2.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—melanoma	3.06e-06	2.75e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ERCC2—melanoma	3.06e-06	2.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CD80—melanoma	3.03e-06	2.72e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APC—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KIT—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—NRAS—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CD44—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GNAQ—melanoma	3.02e-06	2.71e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GNAQ—melanoma	3e-06	2.69e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CD44—melanoma	3e-06	2.69e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—EGF—melanoma	2.99e-06	2.68e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLA2G6—melanoma	2.97e-06	2.66e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—melanoma	2.96e-06	2.65e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—melanoma	2.94e-06	2.64e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CD—melanoma	2.94e-06	2.64e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.93e-06	2.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CTNNB1—melanoma	2.93e-06	2.63e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP17A1—melanoma	2.92e-06	2.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.91e-06	2.61e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ABCB1—melanoma	2.91e-06	2.61e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ALB—melanoma	2.9e-06	2.6e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP1B1—melanoma	2.9e-06	2.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK3—melanoma	2.9e-06	2.6e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.88e-06	2.58e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP1B1—melanoma	2.87e-06	2.58e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1A—melanoma	2.87e-06	2.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—melanoma	2.86e-06	2.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—melanoma	2.84e-06	2.55e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	2.84e-06	2.55e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—melanoma	2.77e-06	2.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF1—melanoma	2.77e-06	2.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRAS—melanoma	2.76e-06	2.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK1—melanoma	2.76e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GNA11—melanoma	2.75e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CD—melanoma	2.7e-06	2.42e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—FASN—melanoma	2.7e-06	2.42e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAP2K1—melanoma	2.68e-06	2.4e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PRKCA—melanoma	2.68e-06	2.4e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—VCAN—melanoma	2.67e-06	2.39e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ALB—melanoma	2.66e-06	2.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CD—melanoma	2.66e-06	2.38e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ERCC2—melanoma	2.65e-06	2.38e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC5A5—melanoma	2.65e-06	2.38e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK3—melanoma	2.65e-06	2.37e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—melanoma	2.6e-06	2.33e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CB—melanoma	2.56e-06	2.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GNAQ—melanoma	2.56e-06	2.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CD44—melanoma	2.56e-06	2.3e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—melanoma	2.56e-06	2.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRAS—melanoma	2.55e-06	2.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FGF2—melanoma	2.55e-06	2.28e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—melanoma	2.54e-06	2.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.54e-06	2.27e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK1—melanoma	2.52e-06	2.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.51e-06	2.25e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.48e-06	2.23e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—melanoma	2.48e-06	2.22e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP1B1—melanoma	2.46e-06	2.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK3—melanoma	2.44e-06	2.19e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—melanoma	2.42e-06	2.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—melanoma	2.39e-06	2.14e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—melanoma	2.39e-06	2.14e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ABCB1—melanoma	2.39e-06	2.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MDM2—melanoma	2.38e-06	2.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—melanoma	2.38e-06	2.13e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—melanoma	2.38e-06	2.13e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ABCB1—melanoma	2.37e-06	2.12e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—melanoma	2.35e-06	2.11e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CB—melanoma	2.35e-06	2.11e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB2—melanoma	2.35e-06	2.11e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—melanoma	2.33e-06	2.09e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PRKCA—melanoma	2.33e-06	2.09e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—melanoma	2.33e-06	2.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK1—melanoma	2.32e-06	2.08e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CB—melanoma	2.32e-06	2.08e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ERCC2—melanoma	2.31e-06	2.07e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP17A1—melanoma	2.25e-06	2.02e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—melanoma	2.23e-06	2e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—melanoma	2.22e-06	1.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—melanoma	2.21e-06	1.98e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.2e-06	1.97e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PRKCA—melanoma	2.2e-06	1.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—melanoma	2.2e-06	1.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—melanoma	2.18e-06	1.96e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ERCC2—melanoma	2.18e-06	1.95e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PRKCA—melanoma	2.18e-06	1.95e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CD—melanoma	2.18e-06	1.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1B—melanoma	2.17e-06	1.95e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.17e-06	1.94e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ERCC2—melanoma	2.16e-06	1.94e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ALB—melanoma	2.15e-06	1.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—melanoma	2.13e-06	1.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—melanoma	2.13e-06	1.91e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CD—melanoma	2.13e-06	1.91e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GNA11—melanoma	2.13e-06	1.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—melanoma	2.12e-06	1.9e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ALB—melanoma	2.1e-06	1.88e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—melanoma	2.1e-06	1.88e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—FASN—melanoma	2.08e-06	1.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—melanoma	2.07e-06	1.86e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CTNNB1—melanoma	2.05e-06	1.84e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC5A5—melanoma	2.05e-06	1.83e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—melanoma	2.03e-06	1.82e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—melanoma	2.02e-06	1.81e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ABCB1—melanoma	2.02e-06	1.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—melanoma	2.02e-06	1.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—melanoma	2.02e-06	1.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—melanoma	2.01e-06	1.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1A—melanoma	2.01e-06	1.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—melanoma	2e-06	1.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NFKB1—melanoma	1.99e-06	1.79e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GNAQ—melanoma	1.98e-06	1.77e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CD44—melanoma	1.98e-06	1.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—melanoma	1.95e-06	1.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—melanoma	1.93e-06	1.73e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—melanoma	1.92e-06	1.72e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CB—melanoma	1.9e-06	1.7e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP1B1—melanoma	1.89e-06	1.7e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—melanoma	1.88e-06	1.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—melanoma	1.87e-06	1.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PRKCA—melanoma	1.86e-06	1.67e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CB—melanoma	1.85e-06	1.66e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ERCC2—melanoma	1.85e-06	1.65e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CD—melanoma	1.84e-06	1.65e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—melanoma	1.84e-06	1.65e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—melanoma	1.83e-06	1.64e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ALB—melanoma	1.82e-06	1.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—melanoma	1.81e-06	1.62e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—melanoma	1.79e-06	1.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.79e-06	1.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRAS—melanoma	1.79e-06	1.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—melanoma	1.79e-06	1.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—melanoma	1.78e-06	1.6e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—melanoma	1.76e-06	1.58e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—melanoma	1.72e-06	1.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK3—melanoma	1.71e-06	1.53e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—melanoma	1.71e-06	1.53e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—melanoma	1.66e-06	1.49e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—melanoma	1.66e-06	1.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—melanoma	1.65e-06	1.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—melanoma	1.65e-06	1.48e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—melanoma	1.64e-06	1.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK1—melanoma	1.63e-06	1.46e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CB—melanoma	1.61e-06	1.44e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CD—melanoma	1.6e-06	1.44e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—melanoma	1.6e-06	1.44e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—melanoma	1.59e-06	1.43e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALB—melanoma	1.58e-06	1.42e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—melanoma	1.56e-06	1.4e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ABCB1—melanoma	1.56e-06	1.4e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—melanoma	1.54e-06	1.38e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.53e-06	1.37e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CD—melanoma	1.51e-06	1.36e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CD—melanoma	1.5e-06	1.34e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALB—melanoma	1.49e-06	1.34e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALB—melanoma	1.48e-06	1.33e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—melanoma	1.46e-06	1.31e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PRKCA—melanoma	1.44e-06	1.29e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—melanoma	1.43e-06	1.28e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ERCC2—melanoma	1.42e-06	1.28e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—melanoma	1.41e-06	1.27e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—melanoma	1.41e-06	1.26e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CB—melanoma	1.4e-06	1.25e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—melanoma	1.39e-06	1.24e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—melanoma	1.39e-06	1.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—melanoma	1.37e-06	1.23e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CB—melanoma	1.32e-06	1.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—melanoma	1.31e-06	1.17e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CB—melanoma	1.31e-06	1.17e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—melanoma	1.31e-06	1.17e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—melanoma	1.29e-06	1.16e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CD—melanoma	1.28e-06	1.15e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—melanoma	1.28e-06	1.14e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALB—melanoma	1.26e-06	1.13e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—melanoma	1.25e-06	1.12e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—melanoma	1.21e-06	1.08e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—melanoma	1.17e-06	1.05e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—melanoma	1.16e-06	1.04e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—melanoma	1.15e-06	1.03e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—melanoma	1.14e-06	1.02e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—melanoma	1.13e-06	1.01e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—melanoma	1.13e-06	1.01e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—melanoma	1.12e-06	1.01e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CB—melanoma	1.12e-06	1e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—melanoma	1.11e-06	9.92e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—melanoma	1.09e-06	9.73e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CD—melanoma	9.89e-07	8.86e-06	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—melanoma	9.79e-07	8.78e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALB—melanoma	9.76e-07	8.75e-06	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—melanoma	9.65e-07	8.65e-06	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—melanoma	9.44e-07	8.47e-06	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—melanoma	9.23e-07	8.28e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CB—melanoma	8.62e-07	7.73e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—melanoma	8.54e-07	7.66e-06	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—melanoma	8.53e-07	7.64e-06	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—melanoma	8.04e-07	7.2e-06	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—melanoma	8e-07	7.17e-06	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—melanoma	7.97e-07	7.14e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—melanoma	7.45e-07	6.68e-06	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—melanoma	6.97e-07	6.25e-06	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—melanoma	6.81e-07	6.1e-06	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—melanoma	6.56e-07	5.89e-06	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—melanoma	6.51e-07	5.83e-06	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—melanoma	5.56e-07	4.99e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—melanoma	5.25e-07	4.71e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—melanoma	4.29e-07	3.85e-06	CbGpPWpGaD
